INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ultragenyx Pharmaceutical Inc. and its officers or directors [1] Group 1: Company Developments - On July 9, 2025, Ultragenyx and Mereo BioPharma Group plc announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta, with a final analysis expected around the end of the year [3] - Following the announcement, Ultragenyx's stock price dropped by $10.41 per share, or 25.11%, closing at $31.04 per share on July 10, 2025 [3] Group 2: Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]